AMPE:NYE-Ampio Pharmaceuticals, Inc (USD)

COMMON STOCK | Biotechnology | NYE

Last Closing Price

USD 1.71

Change

0.00 (0.00)%

Market Cap

USD 0.32B

Volume

1.83M

Average Target Price

N/A
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Ampio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of therapies for the treatment of prevalent inflammatory conditions in the United States. It is developing compounds that decrease inflammation by inhibiting specific pro-inflammatory compounds. The company's product pipeline includes Ampion, which is in phase III clinical trial, is an intra-articular injection for the treatment of osteoarthritis of the knee. Ampio Pharmaceuticals, Inc. has collaborative research agreements to explore new clinical indications for its immunomodulatory drug, Ampion. The company is headquartered in Englewood, Colorado. Address: 373 Inverness Parkway, Englewood, CO, United States, 80112

Company Website : http://www.ampiopharma.com

Address : 373 Inverness Parkway, Englewood, CO, United States, 80112

Employees : 23

Fiscal Year End : December

Currency: USD

Country : USA

Technical Indicators

Beta : 1.75

52 Week High : 2.98

Short Ratio : 4.00

52 Week Low : 0.35

Shorted Shares : 21,520,846

200 Day Moving Average : 1.20

Shorted Shares Previous Month : 22,275,303

50 Day Moving Average : 1.78

Shares Held By Insiders : 75.95999999999999%

Short Percentage : 12.00%

Shares Held by Institutions : 12.01%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-02-27 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
NVO Novo Nordisk A/S

N/A

 USD165.40B 28.94 2.82
ADPT Adaptive Biotechnologies Corpo..

N/A

 USD7.88B 43.96 N/A
BHVN Biohaven Pharmaceutical Holdin..

N/A

 USD5.11B N/A N/A
RCUS Arcus Biosciences, Inc

N/A

 USD2.50B N/A N/A
ADCT ADC Therapeutics SA

N/A

 USD2.04B -99,999.99 N/A
MYOV Myovant Sciences Ltd

N/A

 USD2.04B N/A N/A
ZYME Zymeworks Inc

N/A

 USD1.68B 300.20 N/A
CVM CEL-SCI Corporation

N/A

 USD0.72B N/A N/A
RFL Rafael Holdings, Inc

N/A

 USD0.59B N/A N/A
PFNX Pfenex Inc

N/A

 USD0.44B 268.67 63.90

ETFs Containing AMPE

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 7.55% 32% F 67% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 7.55% 32% F 66% D
Trailing 12 Months  
Capital Gain 185.00% 96% A 96% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 185.00% 96% A 96% A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 51.51% 78% C+ 97% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 51.51% 78% C+ 97% A+
Risk Return Profile  
Volatility (Standard Deviation) 78.93% 30% F 4% F
Risk Adjusted Return 65.25% 89% B+ 75% C
Market Capitalization 0.32B 61% D- 33% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 26.87 40% F 30% F
Price/Book Ratio 33.82 19% F 3% F
Price / Cash Flow Ratio -20.57 82% B- 93% A
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -165.48% 22% F 2% F
Return on Invested Capital -318.11% 15% F 0% N/A
Return on Assets -75.65% 19% F 0% N/A
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 4.00 18% F 21% F
Short Percent 11.79% 16% F 30% F
Beta 1.75 44% F 17% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.